Characterization of Coronary Plaque in Psoriasis and the Impact of Current Therapies

Ashlee L Culver1, Annika S Silfvast-Kaiser2, Alan Menter1,2*

1Texas A&M Health Science Center College of Medicine, TX
2Division of Dermatology, Baylor University Medical Center, Dallas, TX

Abstract

Psoriasis is a systemic inflammatory disease which contributes to an increased risk for cardiovascular disease, specifically coronary artery disease. Patients with psoriasis tend to have greater total coronary plaque burden and more high risk plaque than healthy controls. This likely contributes to the higher rate of myocardial infarction and 4-5 year reduction in lifespan observed in our psoriasis population. With biologic therapy and improvement in PASI scores, total plaque burden and noncalcified coronary plaque decreases as well. Specifically, ustekinumab decreases intima-media thickness and reduces vascular inflammation. Likewise, TNF-α inhibitors decrease vascular inflammation and reduce cardiovascular events in both sexes, and reduce coronary plaque formation in men with psoriasis. This may be due to elevation in glycoprotein acetylation, which is associated with cardiovascular events and elevated in psoriasis. This elevation has also been shown to decrease with adalimumab usage. Despite all of the knowledge gained on this topic, the incidence of myocardial infarction in psoriasis patients currently remains unchanged when compared to prior years. Consequently, we emphasize the need for further research on the unique pathogenesis of psoriatic coronary plaque formation as well as the effect biologic agents have on this coronary plaque in order to improve the wellbeing of this patient population.

Introduction

Psoriasis is a T-cell mediated inflammatory disorder with estimates of prevalence ranging from 0.51% to 11.43% in adults worldwide. The erythematous, scaly plaques characteristic of chronic plaque psoriasis are not only unsightly and uncomfortable for patients, but they also represent the possibility of internal manifestations of the disease. The many comorbidities associated with psoriasis include, but are not limited to, joint disease, depression, metabolic syndrome, and cardiovascular disease. The increased risk for cardiovascular disease has been well documented and is thought to be due to chronic systemic inflammation. This conclusion is based on the understanding that T-helper cells play a central role in the pathogenesis of both atherosclerosis and psoriasis. A surge of research regarding this topic has occurred as the association between psoriasis and cardiovascular disease becomes more widely appreciated. This has resulted in better characterization of cardiovascular risk in these patients, which unfortunately includes a shorter average lifespan. In psoriasis patients with a body surface area (BSA) > 10%, the risk of death has been shown to be significantly increased by about 1.8 times when compared to matched controls without psoriasis. Although a significant increase in mortality has not been definitively shown for those with less than 10% BSA, these
patients may still be at a higher risk for comorbidities such as chronic kidney disease, chronic obstructive pulmonary disease, diabetes, and history of myocardial infarction. In addition, young patients with severe psoriasis actually have the greatest risk for having a myocardial infarction associated with their disease, even after accounting for other traditional risk factors and concomitant health conditions. Therefore, psoriasis has been named an independent risk factor for myocardial infarction.

**Coronary Artery Disease Burden in Psoriasis**

Researchers and clinicians have sought to understand more about coronary artery disease and ways to diagnose and characterize coronary artery plaque in psoriasis patients. Interest has peaked regarding this topic after multiple studies have shown an increased risk of acute coronary syndrome in psoriasis patients, specifically, myocardial infarction. Using coronary angiography, Armstrong et al. was able to establish that psoriasis patients had a higher prevalence of coronary artery disease than their controls, especially with a disease duration of 8 years or greater. In order to assess subclinical atherosclerosis, Mansouri et al. compared coronary artery calcium scores of type 2 diabetics to psoriasis patients with moderate to severe disease activity. This study showed that when considering mean total Agatston scores, both groups had similar amounts of coronary artery calcium present which were 3 times higher than a normal control group.

**Coronary Artery Plaque Characterization**

In order to more completely understand true cardiovascular risk, it is important to not only assess the severity of the coronary plaque in psoriasis patients but also characterize the plaque itself. This allows clinicians to know how to assess the risk in this population to improve diagnostic and prognostic ability. It has been shown that patients with systemic inflammatory diseases, such as HIV, tend to have more noncalcified plaque and high risk plaque. In the same way a small study by Bissonnette et al. showed that patients with psoriasis tend to have an increase in mixed plaques (calcified and noncalcified), as well as a greater mean overall burden of coronary atherosclerosis when compared to controls. This is true even after adjusting for factors like obesity. Recently, *Circulation* published a much larger study, with the goal of using coronary CT angiography to characterize coronary artery plaque in psoriasis when compared to a cohort of hyperlipidemic patients and healthy volunteers. The study demonstrated that psoriasis patients had a significantly greater total coronary plaque burden when compared to the healthy volunteers, as well as greater noncalcified plaque burden than both the hyperlipidemic patients and healthy controls. They had more high risk plaque than healthy individuals as well.

In addition, after one year of biologic therapy, patients who experienced significant improvement in the Psoriasis Area and Severity Index (PASI) score showed a decreased total coronary plaque burden ($\beta=0.45, 95\% CI: 0.23-0.67; p<0.001$) and noncalcified coronary plaque burden ($\beta=0.53, 0.32-0.74; p<0.001$). These values were adjusted for confounding variables such as age, sex, atherosclerotic cardiovascular disease 10-year risk, body mass index, lipid lowering therapy, and systemic/biologic psoriasis treatment. However, in patients who had worsening of their psoriasis, there was an increase in noncalcified coronary artery plaque burden concomitantly. The levels of tumor necrosis factor-alpha (TNF-α) and other inflammatory proteins in patients with improved PASI scores also decreased significantly. Nevertheless, treatment with biologics did not affect insulin resistance or cholesterol efflux capacity in the psoriasis cohort.

**Plaque Formation on the Molecular Level and Targeted Treatments**

Along with the concern for coronary artery disease in psoriasis, comes an interest in understanding more about the pathogenesis of atherosclerosis in these patients at the molecular level, with the hope of offering more targeted treatment options in the future. T-cells are central to the pathogenesis of psoriasis, and they can become stimulated to differentiate into T-helper 1 cells which produce cytokines such as IL-17, TNF-α, and IL-23. These cytokines are known to play a crucial role in driving psoriasis, which is why many current therapies target them specifically. The cytokine IL-36y has recently been linked to psoriasis and angiogenesis as it induces IL-23 which promotes both processes. Although drugs targeting IL-36y have not been developed yet, anti-IL-23 biologic agents are available, including ustekinumab and guselkumab. Ustekinumab, the anti-IL-12/23 medication, has been shown to decrease intima-media thickness, thus promoting the notion that it may improve cardiovascular disease in psoriasis patients. Ustekinumab treatment has also been associated with decreased systemic and vascular inflammation determined by using standardized uptake values with F-fluorodeoxyglucose PET/CT after achieving a reduction in PASI score of 75%.

**Targeted Treatments**

The cytokine IL-36y has recently been linked to psoriasis and angiogenesis as it induces IL-23 which promotes both processes. Although drugs targeting IL-36y have not been developed yet, anti-IL-23 biologic agents are available, including ustekinumab and guselkumab. Ustekinumab, the anti-IL-12/23 medication, has been shown to decrease intima-media thickness, thus promoting the notion that it may improve cardiovascular disease in psoriasis patients. Ustekinumab treatment has also been associated with decreased systemic and vascular inflammation determined by using standardized uptake values with F-fluorodeoxyglucose PET/CT after achieving a reduction in PASI score of 75%.

Guselkumab, a biologic agent that specifically targets IL-23, has shown extraordinary rates of reduction in skin symptom severity in psoriasis patients since becoming available.
medication also affects the pathway involving IL-36y and angiogenesis. The effects of guselkumab on coronary plaque burden and cardiovascular disease in psoriasis patients has yet to be studied, but it would make a major topic for further research. Biologic therapies currently target many of the cytokines previously mentioned, and some have been investigated for their potential cardiovascular benefits in psoriasis patients. A large Danish study of patients with severe psoriasis treated with biological agents or methotrexate showed a lower rate of cardiovascular events when compared to patients following other psoriasis treatment regimens. When specifically considering TNF inhibitors, there is a definite reduction in the progression of plaque in men and women. This also correlates with a subsequent reduction in major adverse cardiovascular events. This reduction may be linked to glycoprotein acetylation, which has recently been identified as a marker for future cardiovascular events. Psoriasis patients with more severe disease tend to have higher levels of glycoprotein acetylation associated with subclinical cardiovascular disease, and the TNF-α inhibitor, adalimumab, decreases it significantly. Moreover, adalimumab now has extensive safety data through the ESPRIT registry without increased incidence rates for adverse events, serious infections, or malignancies. Therefore, clinicians can use adalimumab with confidence due to its proven safety and efficacy in treating psoriasis, with hopes that it may also have some positive effect on a patient's psoriatic cardiovascular disease.

As mentioned previously, the metabolic syndrome is more prevalent in psoriasis patients, and it is known to contribute to atherosclerosis and cardiovascular risk in general. Researchers have hypothesized that alterations in circulating adipokines such as leptin, adiponectin, and resistin were responsible for promoting metabolic syndrome in psoriasis patients. In an effort to understand this relationship, Wolk et al. explored this topic and found that standard psoriasis treatment resulted in a decrease of resistin levels, without a significant reduction in adiponectin or leptin levels. Further investigation is warranted in order to uncover the true clinical significance of these findings.

Despite the recent surge in research investigating cardiovascular risk in psoriasis, cumulative incidence of myocardial infarction in today’s psoriatic patients remains unchanged when compared to psoriatic patients of years prior. As we are still unable to improve cardiovascular mortality in these patients, more research is necessary to exploit current treatment regimens for this specific indication and uncover new avenues through which medications can be developed.

Summary

In conclusion, severe psoriasis and psoriatic arthritis are associated with greater overall coronary artery plaque burden, as well as more vulnerable plaque types, when compared to controls. This explains the increased cardiovascular risk in psoriasis patients contributing to a shorter average lifespan. Many of the biologics have shown a reduction of coronary artery disease severity after prolonged treatment. However, despite this proven benefit and the extensive safety data on many of these agents, specifically adalimumab, the risk of myocardial infarction has remained the same in psoriasis patients. The need for more research to re-evaluate our current treatment recommendations for psoriasis in the context of coronary artery disease remains apparent, as does the development of specific therapies that are more targeted toward this life threatening complication of psoriasis.

References


